The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I clinical trial on pomalidomide and dexamethasone in treating patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) or primary vitreoretinal lymphoma (PVRL).
 
Han W. Tun
Research Funding - Celgene (Inst); Mundipharma (Inst); Spectrum Pharmaceuticals (Inst)
 
Patrick B. Johnston
No Relationships to Disclose
 
Christian Grommes
Research Funding - Pharmacyclics (Inst)
 
Craig B. Reeder
Research Funding - Celgene (Inst); Millennium (Inst); Novartis (Inst)
 
Antonio Marcilio Padula Omuro
Consulting or Advisory Role - Alexion Pharmaceuticals; AstraZeneca; Bristol-Myers Squibb; Inovio Pharmaceuticals; Juno Therapeutics; Merck; Oxigene; Stemline Therapeutics
 
David M Menke
No Relationships to Disclose
 
John A. Copland
Research Funding - Plexxikon (Inst); xenon pharma (Inst)
 
Lisa Marie DeAngelis
Consulting or Advisory Role - BMJ publishing; CarThera; Juno Therapeutics; Roche; SapVax
 
Thomas E. Witzig
Stock and Other Ownership Interests - Valeant Pharmaceuticals International
Consulting or Advisory Role - Celgene; Seagen
Research Funding - Acerta Pharma (Inst); Celgene (Inst); Novartis (Inst); Spectrum Pharmaceuticals (Inst)